Myasthenia Gravis: Predicting Patient Response to Precision Medicine
- Here's a cleaned-up version of the text, removing the extraneous code while preserving the content and links:
- They discuss important considerations in the move toward a precision medicine approach in the space that include MG immunopathologic basis, defining disease subgroup, and patient comorbidities.
- Doran, MD, FACP, Endowed Chair in Peripheral Neuropathy at UT Health San Antonio, and Stein is the chief of neurology at St.
Here’s a cleaned-up version of the text, removing the extraneous code while preserving the content and links:
(MG). They discuss important considerations in the move toward a precision medicine approach in the space that include MG immunopathologic basis, defining disease subgroup, and patient comorbidities.
Bhavaraju-Sanka is the John H. Doran, MD, FACP, Endowed Chair in Peripheral Neuropathy at UT Health San Antonio, and Stein is the chief of neurology at St. Joseph’s Health.
Rewatch part 1 of their interview to learn about ensuring broad access to new MG treatments and part 2 where they address the roles of holistic care and patient-physician collaboration.
This transcript was lightly edited for content.
Key changes made:
* Removed all the <astro-island> tags and associated attributes.
* converted the link-related code within those tags into standard Markdown links: [link text](URL).
* Preserved the text content and the links themselves.
* Removed the initial 0,"24da83a1ff3e"]} which appeared to be extraneous.